1: Sitagliptin, a DPP-4 Inhibitor, Reduces the Incidence of Acute GVHD After Stem-Cell Transplant
2: Pembrolizumab Shows Long-Term Benefits in
Patients with Metastatic Colorectal Cancer and MSI-H or dMMR
Sarah M. Hayes, PharmD, BCOP, Jeremy Whalen, PharmD, BCOP, Nick Schutz, PharmD, Joseph Levine, MD
Infusion-related reactions present a daily challenge to any provider involved in the administration of chemotherapy. These reactions range from mild to life-threatening and may significantly alter the planned course of therapy for patients with cancer.